Brief: EMA’s PRAC Says Insufficient Evidence to Link Doxycycline To Suicidality Risk

Astellas Pharma

29/11/2024 11:53

Nov 29 (Reuters) - EMA's PRAC:
    * SAYS ON DOXYCYCLINE: CURRENTLY AVAILABLE EVIDENCE NOT
SUPPORTING
LINK WITH RISK OF SUICIDALITY
    * EMA: PRAC HAS AGREED TO DHPC INFORMING OF RISK OF
DRUG-INDUCED
LIVER INJURY WITH VEOZA (FEZOLINETANT)
    * EMA: PRAC RECOMMENDS MONITORING OF LIVER FUNCTION BEFORE
AND
DURING TREATMENT WITH VEOZA (FEZOLINETANT)
    * SAYS ON VEOZA: TREATMENT SHOULD BE DISCONTINUED IN CERTAIN
CASES
OF TRANSAMINASE, BILIRUBIN ELEVATIONS

Source text:  ID: 
Further company coverage:  4503.T 

 ((Reuters.Briefs@thomsonreuters.com;))